IDH1 and cancer: Although we acknowledge that the current study does not address the efficacy of metformin against cancer cell models naturally bearing clinically relevant IDH1 mutations, our findings provide a direct mechanistic link to the association between metformin use and a significant reduction in incidence of intrahepatic cholangiocarcinoma (IHCC) in patients with diabetes [87].